Abstract: A fixing device includes a belt member that cyclically moves, a pressing unit that comes into contact with the belt member and presses a recording medium moving between the belt member and the pressing unit, and a heat source that includes a base material, a resistance heating element disposed on a surface of the base material along a longitudinal direction of the base material, and an insulator covering the resistance heating element and that comes into contact with the pressing unit via the belt member to heat an inner surface of the belt member, in which the insulator is formed to cover a corner portion of the base material in a direction of movement of the belt member.

Abstract: A data extraction system includes a registration apparatus, a data storage apparatus, and a query apparatus. The registration apparatus generates registration data including first information obtained by encrypting secret information, which is information that a user wishes to keep secret, by using a secret key and second information obtained by encrypting the secret key by using at least biological information of the user. The data storage apparatus holds the registration data. The query apparatus acquires the registration data by generating a query for acquiring the registration data from the data storage apparatus, extracts the secret key from the registration data by using biological information of the user, and extracts the secret information from the registration data by using the extracted secret key.

Abstract: In the system to collect image data for expressway inspection according to the present invention, in an automobile running on an expressway, a local area network including a shooting means, a storage means, an image extraction means, a positional information acquisition means, and a wireless communication means is constructed. The shooting means shoots still images at predetermined time interval, and for each time the shooting is performed, outputs the obtained image data to the storage means. The storage means recognizes positional information acquired at the timing of shooting the image data from the positional information acquisition means as shooting location, and stores the image data in relation with the shooting location.

Abstract: A conventional biometric authentication system has been time-consuming and labor-intensive for users since the users are requested to re-register their biometric information. According to an aspect of the present disclosure, a biometric authentication system includes an update value generation unit configured to generate an update value, a first update processing unit configured to update, using the update value, a template generated based on biometric information, and a second update processing unit configured to update, using the update value, a verification key generated along with the template based on the biometric information using the update value.

Abstract: A medical system includes: an endoscope; an ultrasonic probe; and a control device that is connected to the endoscope and the ultrasonic probe, generates a display image from a captured image acquired by the endoscope, and generates an echo image from an ultrasonic wave acquired by the ultrasonic probe, wherein the control device acquires a first echo image in which a target tissue is displayed on a central axis, acquires a second echo image obtained by scanning a cross section different from the first echo image at a reference position of the ultrasonic probe from which the first echo image was acquired, and compares a central axis of the second echo image with a position of the target tissue in the second echo image.

Abstract: An object is to provide a pavement condition rating system which utilizes a road surface image based on perspective and which is extracted from a moving image obtained by traveling while photographing a road surface of a road, makes it possible to use the whole of an image area of a road surface included in a road surface image for detection of damage, and is less susceptible to damage erroneous detection. By using a plurality of images obtained by combining image of damage included in a road surface still image based on perspective and definitions of the damage as damage learning data, an object detection model is built.

Abstract: A 1,2,3,4-tetrahydroquinoxaline compound represented by the following formula: In the formula (1), R1 represents substituents such as a halogen, an alkyl, a cycloalkyl, an aryl or a heterocyclic group; p represents 0 to 5; R2 represents substituents such as a halogen, an alkyl, a hydroxyl or an alkoxy group; q represents 0 to 2; R3 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkylcarbonyl or an arylcarbonyl group; R4 and R5 independently represent substituents such as hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; R6 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; A represents an alkylene; R7 represents OR8, NR8R9, SR8, S(O)R8, S(O)2R8; R8 and R9 independently represent substituents such as hydrogen, an alkyl or an alkenyl; and X represents O or S.

Abstract: The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye).

Abstract: A method for treating a non-ocular inflammatory disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound represented by the following formula (1) or a salt thereof: R1 represents: R2 represents a lower alkyl group, a lower cycloalkyl group or an aralkyl group; R3 represents a lower alkyl group; R4, R5, R6 or R7 each represents a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a cyano group or a nitro group; m, n, p or q each represents 0, 1 or 2; in the case where m, n, p or q is 2, each of R4, R5, R6 or R7 is the same or different.

Abstract: A 1,2,3,4-tetrahydroquinoxaline compound represented by the following formula: In the formula (1), R1 represents substituents such as a halogen, an alkyl, a cycloalkyl, an aryl or a heterocyclic group; p represents 0 to 5; R2 represents substituents such as a halogen, an alkyl, a hydroxyl or an alkoxy group; q represents 0 to 2; R3 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkylcarbonyl or an arylcarbonyl group; R4 and R5 independently represent substituents such as hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; R6 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; A represents an alkylene; R7 represents OR8, NR8R9, SR8, S(O)R8, S(O)2R8; R8 and R9 independently represent substituents such as hydrogen, an alkyl or an alkenyl; and X represents O or S.

Abstract: A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-dihydroquinoline compound.

Abstract: A method for preventing or treating a metabolic disorder, an inflammatory disease, an autoimmune disease, an allergic disease, a central nervous system disease, a cardiovascular disease, a homeostasis-related disease or glaucoma, involving administering a compound or a salt thereof, the compound having the following formula (1): wherein R1 represents alkyl, cycloalkyl, aryl, heterocyclic or aralkyl; R7 represents cycloalkyl, aryl or heterocyclic; W represents oxygen or NR8, Y represents alkylene, Z represents oxygen, sulfur, OCO or NR9; R2, R3, R4, R6, R8 and R9 represent hydrogen or alkyl.

Abstract: A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-dihydroquinoline compound or a pharmaceutically acceptable salt thereof.

Abstract: An object of the present invention is to synthesize a novel 1,2,3,4-tetrahydroquinoxaline derivative represented by formula (1) and to find a pharmacological action of the derivative. In the formula, the R1 represents a halogen, an alkyl, cycloalkyl, aryl or heterocyclic group, or the like; p represents 0 to 5; R2 represents a halogen, an alkyl, hydroxyl or alkoxy group, or the like; q represents 0 to 2; R3 represents hydrogen, an alkyl, alkenyl, alkylcarbonyl or arylcarbonyl group, or the like; R4 and R5 independently represent hydrogen, a halogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; R6 represents hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; A represents an alkylene; R7 represents OR8, NR8R9, SR8, S(O)R8, S(O)2R8; and X represents O or S.

Abstract: A method for treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-hydroquinoline compound.

Abstract: The present invention is related to glucocorticoid receptor agonists comprised of a compound represented by formula (1) which is 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative or a salt thereof and novel pharmacological effects of the glucocorticoid receptor agonists. In the formula (1), R1 represents formula (2a), (3a), (4a) or (5a); R2 represents —(CO)—R8, —(CO)O—R9, or the like; R2—O— is substituted at the 4- or -5-position of benzene ring A; R3 represents a lower alkyl group; R4, R5, R6 or R7 represents a halogen atom, a lower alkyl group which may have a substituent, or the like; m, n, p or q represents 0, 1 or the like; R8, R9 or the like represents a lower alkyl group which may have a substituent, a lower alkenyl group, or the like.

Abstract: A method of preventing or treating a glucocorticoid receptor-related disease involving administering a therapeutically effective amount of a 1,2-dihydroquinoline compound or a pharmaceutically acceptable salt thereof.

Abstract: An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viral

Abstract: A carbon porous body (ICY) includes a carbon skeleton containing carbon atoms, wherein the carbon skeleton includes carbon main sections and carbon linking sections mutually linking the carbon main sections; a distance D1 between adjacent carbon main sections and a distance D2 between adjacent carbon linking sections satisfy the relationship of D1<D2; the carbon main sections are arranged three-dimensionally, regularly and symmetrically; and a specific surface area of the carbon porous body is not less than 1,300 m2/g and/or the pore capacity of the carbon porous body is not less than 1.5 cm3/g.

Abstract: A carbon porous body (ICY) includes a carbon skeleton containing carbon atoms, wherein the carbon skeleton includes carbon main sections and carbon linking sections mutually linking the carbon main sections; a distance D1 between adjacent carbon main sections and a distance D2 between adjacent carbon linking sections satisfy the relationship of D1<D2; the carbon main sections are arranged three-dimensionally, regularly and symmetrically; and a specific surface area of the carbon porous body is not less than 1,300 m2/g and/or the pore capacity of the carbon porous body is not less than 1.5 cm3/g.